Needham & Company Starts Collegium Pharmaceutical (COLL) at Buy

Needham & Company initiates coverage on Collegium Pharmaceutical (NASDAQ: COLL) with a Buy rating and a price target of $28.00.

Analyst Serge Belanger commented, "We are initiating coverage of Collegium Pharmaceutical, Inc. (COLL), an emerging specialty pharma leader in the abuse-deterrent opioid pain treatment market, with a Buy rating and $28 PT. Collegium is focused on the development and commercialization of next-gen abuse-deterrent products using its proprietary DETERx platform technology for treating chronic pain and other diseases. The lead product candidate, Xtampza ER, is an abuse-detrrent extended-release oral formulation of oxycodone that is currently under FDA review with a 10/12/15 PDUFA. We believe data from Xtampza ER's clinical development program supports a differentiated and potential best-in-class label that should allow the product to have a strong competitive position in the oxycodone ER segment and the overall ER/LA opioid market."

For an analyst ratings summary and ratings history on Collegium Pharmaceutical click here. For more ratings news on Collegium Pharmaceutical click here.

Shares of Collegium Pharmaceutical closed at $17.00 yesterday.

You May Also Be Interested In

• Needham Starts Faeth Therapeutics (FTH) at Buy
• Ferrovial SA (FER:SM) (FRRVF) Reiterated at Buy by UBS on Winning Bid For Tennessee Project
• Barclays flags an "attractive entry point" in this pharma stock